Achilles is mainly engaged in the manufacture and sale of shoes, plastic products and industrial materials. Along with its subsidiaries and associated companies, Co.'s principal business segments are shoes, plastic products, and industrial material. Co.'s principal products are shoes such as "ACHILLES SORBO," "SYUNSOKU LemonPie, " "SYUNSOKU DANCE," "SYUNSOKU BABY," and "SPALDING"; synthetic leather "Super Carbon" for car seats, paste leather "Partner" for car seats, and paste leather for car door molds; and ranging from interior materials that enhance the look of the home to insulating materials and rigid fluorocarbon-free urethane foam insulating materials.
Cellectis is a gene-editing company employing its core proprietary technologies to develop products in the field of immuno-oncology. UCART19 is Co.'s lead product. UCART19 is an engineered T-cell product which drives its ability to target and kill CD19-bearing cells, such as B-cell malignancies. Co. is also developing wholly-owned product candidates UCART123, UCARTCS1 and UCART38, which are in various stages of development. UCART 123, UCARTCS1 and UCART38 are engineered T-cell products that bear CARs that seek to kill cells expressing targets CD123, CS1 and CD38, respectively, which are found in other hematologic tumors, such as acute myeloid leukemia, or AML, and multiple myeloma, or MM.
Transgene Biotek is a biotechnology company based in India. Co. is engaged in the development of therapeutic and preventative pharmaceuticals. Co. maintains a product portfolio which includes therapeutic areas such as Bio-generics, Oncology and New Drug Delivery Systems among others. Co.'s products are categorized under 4 main technology platforms: Bio-Generic Drugs, which includes Orlistat, Tacrolimus and recombinant Erythropoietin; Novel Drug Delivery Technology for the oral delivery of protein drugs, with the first two targets being Insulin and Hep B vaccine; platforms for drugs against auto-immune diseases; and Oncology drugs encompassing RNAi technology as well as monoclonal antibodies.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Transgene reported FY 2022 financial results and provided a corporate update. The financial figures were largely in line with expectations. The Company reported a net loss of EUR 32.8m in 2022 (vs EUR 19.5m in 2021), including an R&D spend of EUR 32.2m (vs EUR 32.9m in 2021). At the end of 2022
Cellectis is a clinical-stage biotechnological company developing therapies based on its flagship gene-editing tool TALEN. Cellectis is primarily focused on the development of allogeneic CAR Ts (derived from healthy donors) for the treatment of haematological malignancies and solid tumours. At pres
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.